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ABSTRACT
Radiation-induced pancytopenia proved to be a suit-
able model system in mice and rhesus monkeys for study-
ing thrombopoietin (TPO) target cell range and efficacy.
TPO was highly effective in rhesus monkeys exposed to
the mid-lethal dose of 5 Gy (300 kV x-rays) TBI, a model
in which it alleviated thrombocytopenia, promoted red
cell reconstitution, accelerated reconstitution of immature
CD34+ bone marrow cells, and potentiated the response to
growth factors such as GM-CSF and G-CSF. In contrast
to the results in the 5 Gy TBI model, TPO was ineffective
following transplantation of limited numbers of autolo-
gous bone marrow or highly purified stem cells in mon-
keys conditioned with 8 Gy TBI. In the 5 Gy model, a
single dose of TPO augmented by GM-CSF 24 h after TBI
was effective in preventing thrombocytopenia. The strong
erythropoietic stimulation may result in iron depletion,
and TPO treatment should be accompanied by monitor-
ing of iron status. This preclinical evaluation thus identi-
fied TPO as a potential major therapeutic agent for
counteracting radiation-induced pancytopenia and
demonstrated pronounced stimulatory effects on the
reconstitution of immature CD34+ hemopoietic cells with
multilineage potential. The latter observation explains
the potentiation of the hematopoietic responses to
G-CSF and GM-CSF when administered concomitantly.
It also predicts the effective use of TPO to accelerate
reconstitution of immature hematopoietic cells as well
as possible synergistic effects in vivo with various other
growth factors acting on immature stem cells and their
direct lineage-committed progeny. The finding that a
single dose of TPO might be sufficient for a clinically
significant response emphasizes its potency and is of
practical relevance.
The heterogeneity of the TPO response encountered
in the various models used for evaluation points to mul-
tiple mechanisms operating on the TPO response and
heterogeneity of its target cells. Mechanistic mouse
studies made apparent that the response of multilineage
cells shortly after TBI to a single administration of TPO
is quantitatively more important for optimal efficacy
than the lineage-restricted response obtained at later
intervals after TBI and emphasized the importance of a
relatively high dose of TPO to overcome initial c-mpl-
mediated clearance. Further elucidation of mechanisms
determining efficacy might very well result in a further
improvement, e.g., following transplantation of limited
numbers of stem cells. Adverse effects of TPO adminis-
tration to myelosuppressed or stem cell transplanted
experimental animals were not observed. Stem Cells
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INTRODUCTION
The identification of thrombopoietin (TPO) [1-4] as the
major regulator of thrombocyte production [5, 6] has resulted
in novel insights in the regulation of immature hemopoietic
cell differentiation [7-9] and has potentially provided a ther-
apeutic approach for counteracting thrombocytopenic states,
in particular those associated with intensive cytoreductive
treatment of malignancies. The pharmaceutical development
of TPO for such applications requires demonstration of effi-
cacy in experimental animal models, either as a single agent
or in conjunction with other cytokines. In view of the gener-
ally complex receptor distribution patterns of growth factors
[10-12], interactions resulting from concurrent administra-
tion of the growth factors are difficult to predict by any other
approach than detailed experimental animal in vivo studies.
Myelosuppression is a serious complication of current
chemotherapy regimens, resulting in life-threatening neutrope-
nia and thrombocytopenia and hampering full deployment of
anticancer therapy. Both G-CSF and GM-CSF treatment have
become established therapeutics [13-17] for alleviating
cytopenia, in particular the neutropenia resulting from inten-
sive cytoreductive treatment [18]. Although G-CSF and GM-
CSF are grossly similar in pharmaceutical profile [18, 19],
GM-CSF has advantages in that it also stimulates megakary-
ocytopoiesis and monocyte differentiation [20, 21]. The ben-
eficial effects of both GM-CSF and G-CSF on neutropenia
following cytoreductive treatment are in most studies
restricted to an earlier recovery of approximately five days,
less in dose-intensified chemotherapy [15, 17, 22], on a total
median neutropenia of about 20-25 days. It is therefore of
considerable importance to select combinations of growth
factors that provide optimal costimulatory efficacy. Optimal
co-stimulation may result in particular from growth factors
that promote reconstitution of immature multilineage cells.
Radiation is an effective and controllable agent for induc-
ing myelosuppression and is the most effective single agent
for high-dose eradicative cancer treatment and for immuno-
suppression. For the preclinical evaluation of TPO, we have
made use of rhesus monkeys exposed to the mid-lethal dose
of 5 Gy TBI (300 kV x-rays [23]) as well as the lethal dose of
8 Gy TBI followed by an autologous transplant of highly puri-
fied stem cells. The 5 Gy TBI dose results in a profound pan-
cytopenia for three weeks, whereas 8 Gy irradiated monkeys
need a transplant to prevent protracted pancytopenia and mor-
tality due to transfusion refractoriness. Studied parameters
included, apart from blood cell counts, assessment of imma-
ture bone marrow cells as well as monitoring of adverse
effects. To assess combination treatment, priority was given
to those growth factors which are likely to be used clinically
in conjunction with TPO, i.e., GM-CSF and G-CSF. In this
summary paper, we focus on the myelosuppression data and
mechanisms of action-promoting efficacy and briefly discuss
the transplantation experiments. The findings in rhesus mon-
keys prompted us to return to more basic studies in mice to
elucidate some of the relevant mechanisms. In mice, we cali-
brated the 5 Gy x-rays of the monkeys to 6 Gy g -rays to
accomplish a similar level of myelosuppression, in keeping
with the relative biological effectiveness (RBE) of g -rays and
a similar duration of pancytopenia.
THROMBOPOIETIN AS A SINGLE AGENT IN
MYELOSUPPRESSED RHESUS MONKEYS: PROMINENT
THROMBOPOIETIC AND ERYTHROPOIETIC STIMULATION
WITH IRON DEPLETION, LACK OF A NEUTROPHIL
RESPONSE, AND ACCELERATED BONE MARROW CD34+
CELL RECOVERY
The effectiveness of TPO in alleviating thrombocytopenia
was initially evaluated in a placebo-controlled study involving
rhesus monkeys exposed to 5 Gy TBI, using supraoptimal
treatment with human recombinant TPO (10 µg/kg/d, s.c., day
1-21 after TBI) [24, 25]. The TPO treatment appeared to be
highly effective in preventing thrombocytopenia, with nadirs
for thrombocytes on average far above 100 · 109/l; this repre-
sented a greatly accelerated recovery to normal values with no
need for thrombocyte transfusions, whereas placebo controls
required two to six platelet transfusions. TPO appeared to act
selectively in that neutrophil regeneration was not influenced,
but the red cell lineage recovery was prominently stimulated
with exponential reticulocyte regeneration initiated 10 days
earlier than in placebo-treated animals. The reticulocytosis was
followed by a normoblastosis which occurred earlier and was
more pronounced than in placebo-treated monkeys and was
accompanied by elevated lactic dehydrogenase (LDH) serum
levels, attributed to a rapid and partly inefficient erythro-
poiesis. The effect of TPO on the red cell lineage was also
reflected in a less profound nadir for hemoglobin and hemat-
ocrit values than in placebo controls. Simultaneous TPO and
G-CSF were as effective as TPO in preventing thrombocy-
topenia, although platelet levels did not rise to the supranormal
levels seen with TPO alone. A similar dampening effect of
G-CSF on the TPO response has been described in mice [26]
and might be related to the protracted thrombocytopenia
observed in stem-cell-transplanted monkeys [27] which were
treated with G-CSF. The neutrophil recovery was greatly aug-
mented compared with G-CSF treatment alone, resulting in a
less profound nadir and a recovery that started much earlier,
as was similarly observed for monocyte, CD11b+, CD16+,
and CD56+ cell reconstitution. In addition, TPO strongly pro-
moted the recovery of bone marrow cellularity and granulo-
cyte/macrophage and erythroid progenitor cells, as was also
reflected by a difference of two orders of magnitude with con-
trols in bone marrow CD34+ cells in the second week of treat-
ment, whereas G-CSF had no influence. In magnitude, this
effect surpassed that of any other growth factor tested in the
same animal model, including interleukin 3 (IL-3) and IL-6
(unpublished observations). There was no effect of TPO on
hemostasis parameters, and adverse systemic effects—
apart from iron depletion due to prominent erythropoiesis
stimulation—were not observed for either growth factor.
The thrombopoiesis-stimulating effect of TPO was
already sufficiently effective in the first week of treatment,
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as was clear from the increasing platelet numbers as early as
day 8, as opposed to placebo controls which did not reach sim-
ilar levels before the fourth week after TBI. Also, the effect on
bone marrow cellularity and immature bone marrow cells is
already clear at the end of the second week of treatment.
Therefore, the dose schedule of 21 consecutive days of
treatment was supraoptimal, as was also evident from the
supranormal platelet numbers reached in the second and
third week after TBI; this is consistent with the observation
in a mouse model for thrombocytopenia that a single dose of
TPO given 24 h after the cytoreductive therapy is as effective
as daily dosing for eight consecutive days [28]. The effect of
a single injection in this model was also highly dose-depen-
dent and shows that TPO is clearly more effective in stimu-
lating platelet recovery than other growth factors known to
stimulate platelet pro-
duction, such as IL-6
[29-32], IL-11 [33, 34],
IL-3 [31, 32], and IL-1
[35]. All of these
cytokines stimulate plate-
let production, but not
all are sufficiently effec-
tive for preventing thrombocytopenia at tolerable doses in
view of adverse effects.
A central issue of TPO treatment is prevention of bleeding
as a consequence of myelosuppression. In monkeys, donor
thrombocytes were transfused at the level of 40 · 109/l, which
coincides with the first appearance of petechiae and other
bleeding; this therapy was chosen to prevent undue deaths due
to hemorrhages. For obvious reasons, this level is higher than
used for human patients, where instructions can be given and
sensitization to alloantigens should be avoided. However, as
could be extrapolated from the post-irradiation drop in throm-
bocyte counts after the first week and the first ascending
counts in the third week after TBI in placebo-treated monkeys
and as demonstrated in historical controls [36-38], without
transfusions the thrombocytes would have dropped to levels
lower than 10 · 109/l within two days after the first transfusion.
It can thus be concluded that the TPO treatment, which pre-
vented the decline of thrombocyte counts to levels lower than
100 · 109/l early in the second week after irradiation, also
effectively prevented the propensity for bleeding.
The TPO effect on early hematopoietic progenitor cells of
different lineages was unexpected but is in line with other
observations [39, 40] and consistent with the observation that
its receptor is present on immature progenitor cells [7]. As
megakaryocytes are capable of releasing various growth fac-
tors [41, 42], the effect observed may be an indirect conse-
quence of stimulation of the megakaryocyte lineage.
Alternatively, TPO may synergize directly with growth factors
such as kit ligand or flt-3 ligand to stimulate immature cells.
Evidence for such a synergy has been provided by in vitro
experiments [43-45]. The accelerated recovery of GM pro-
genitor cells may explain the augmented response to G-CSF
along the neutrophil and monocyte lineages, also reflected
by CD11b positive cells. Apparently, G-CSF also stimulated
the CD16/CD56 positive lineage, thought to represent natural
killer cells originating in the bone marrow [46]. Since the
G-CSF dose schedule was supraoptimal in this study, the aug-
mented responses to G-CSF are best explained by increased
numbers of progenitor cells along the GM lineage.
The erythroid lineage was consistently shown to be
involved in the TPO response in vitro and in vivo [24, 40, 47,
48]. In normal mice and primates, TPO selectively stimulated
thrombocyte production, leaving other lineages unaffected. In
myelosuppression models,
multilineage effects were
mainly of an erythroid
nature [28, 40, 49]. The
effect of TPO on the red
cell lineage, like its throm-
bopoietic effect, occurred
very early after irradiation
with exponential reticulocyte regeneration beginning after the
first week of treatment, 10 days earlier than in placebo and G-
CSF-treated controls. Reticulocytosis was followed by a nor-
moblastosis, which was accompanied by elevated LDH serum
levels, both attributed to the rapid and inefficient erythro-
poiesis. As a result, hemoglobin concentrations and hemat-
ocrits stabilized earlier at higher levels. However, this effect
was not followed by a rapid recovery to normal values due to
the development of a microcytic, hypochromic anemia. Iron
depletion was directly demonstrated by measurements of total
serum iron and total iron binding capacity and could be pre-
vented by prophylactic i.m. iron before TBI or corrected by
i.m. iron after TPO treatment. Based on these findings, iron
status needs to be assessed before and monitored during TPO
treatment. It should again be noted that the TPO administration
described here was more intensive than required to normalize
platelet levels and will not likely be necessary for the clinical
therapy of myelosuppressed patients. It is not clear why in
TPO-treated monkeys the normoblastosis followed the reticu-
locytosis, a pattern reverse to that which is seen with other
growth factors such as IL-3 [50] and GM-CSF (unpublished
observation). Since the normoblastosis was highly reduced in
monkeys prophylactically supplemented with iron, the pat-
tern observed might be related to the developing iron defi-
ciency resulting in ineffective erythropoiesis in the course
of TPO-stimulated hematopoietic reconstitution.
Likely, the iron deficiency originated from a precarious
iron balance in rhesus monkeys similar to that in humans,
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A central issue of TPO treatment
is prevention of bleeding as a 
consequence of myelosuppression.
resulting in latent iron deficiency even before radiation expo-
sure. This is supported by the observation that the mean cor-
puscular erythrocyte volume of the animals before treatment
was 75-80 fl and rose to 90 fl in otherwise untreated monkeys
subjected to iron supplementation. The latent iron deficiency
may then be caused either by diet, malabsorption due to the
pre-irradiation antibiotic regimen, parasitic infection, or some
other process related to iron absorption. The iron depletion of
TPO-treated monkeys is reminiscent of erythropoietin-
induced iron deficiency anemia in patients with end-stage
renal failure [51-53]. A similar mechanism is proposed for the
iron deficiency anemia occurring with TPO. Supplementation
of iron before and careful monitoring during treatment proved
to be necessary for all patients receiving erythropoietin.
LACK OF EFFICACY
OF TPO AND
G-CSF IN MONKEYS
SUBJECTED TO
HIGH-DOSE TBI AND
TRANSPLANTATION
OF AUTOLOGOUS,
HIGHLY PURIFIED
STEM CELLS
The efficacy of recom-
binant human TPO and
recombinant human G-
CSF in stimulating
platelet and neutrophil
recovery was evaluated
in a placebo-controlled
study involving transplantation of limited numbers (1-3 ·
104/kg) of highly purified autologous stem cells
(CD34++/RhLA-DRdull) after 8 Gy TBI (x-rays) in rhesus
monkeys [27]. The grafts shortened 8 Gy TBI-induced pro-
found pancytopenia from five to six weeks to three weeks.
Daily administration of TPO (10 µg/kg/d s.c., day 1-21 after
TBI) did not prevent thrombocytopenia nor did it signifi-
cantly stimulate regeneration to normal platelet values. With
the possible exception of reticulocytes, other cell lineages
were not influenced either. Simultaneous treatment with
TPO and G-CSF (5 µg/kg/d, s.c., day 1-21 after TBI), tested
in two monkeys, showed heterogeneous results. In one mon-
key, neutrophil regeneration was slightly promoted (values
>0.5 · 109/l at day 15), whereas the other monkey regener-
ated in the same pattern as placebo-treated controls. Platelet
and reticulocyte regeneration was augmented in the monkey
which regenerated its neutrophils faster, whereas the other
developed protracted thrombocytopenia. G-CSF alone did
not stimulate neutrophil regeneration. It did not affect the
red cell lineage, and in one of three monkeys, a profound
and long-lasting thrombocytopenia developed. To test
whether the size or cellular composition of the graft was
responsible for the lack of efficacy of TPO, three monkeys
were transplanted with unfractionated bone marrow cells in
a cell dose of 107/kg. TPO treatment in this setting again did
not prevent thrombocytopenia either, and recovery to nor-
mal platelet values was, at best, only slightly accelerated.
In monkeys irradiated with 5 Gy TBI which did not
receive a transplant, TPO (10 µg/kg/d) had a very prominent
effect on platelet recovery, as reflected by much less pro-
found platelet nadirs as well as an accelerated recovery to
normal values, resulting in full prevention of thrombopenia
[24]. Since the experimental conditions were calibrated in
such a way that the duration of thrombocytopenia and the
platelet recovery pattern
were the same for the
placebo-treated monkeys
in both models, the differ-
ent responses to TPO are
most remarkable. In prin-
ciple, the difference in
efficacy of TPO in the
stem cell transplant model
and the myelosuppression
model may be attributed
to: A) the dose of TPO
chosen; B) the difference
in radiation dose which
may have caused more
stromal damage in the
stem cell transplant model,
or C) the composition of the cell populations from which
hematopoietic reconstitution originated.
The dose and dose schedule of TPO were based on pilot
dose-finding experiments in normal mice and rhesus monkeys
and found to be supraoptimal. The dose schedule chosen was
also found to be supraoptimal in the myelosuppression model
in that very high levels of platelets were reached within two
weeks. In addition, the TPO levels measured in the placebo
controls demonstrated that full platelet reconstitution was
reached in four weeks after TBI. Apparently, the elevated
endogenous TPO levels, which were more than one order of
magnitude lower than those obtained with exogenous TPO,
were sufficient. Therefore, it is improbable that the ineffec-
tiveness of TPO in the transplant model was attributable to the
dose and dose scheduling of TPO.
The difference between 5 Gy and 8 Gy TBI may have
resulted in a difference in stromal damage, thereby
impairing platelet reconstitution at the higher dose of TBI.
First, in the placebo control monkeys, the kinetics of
platelet reconstitution were very similar, if not identical,
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Since the experimental conditions
were calibrated in such a way 
that the duration of thrombocytopenia
and the platelet recovery pattern were
the same for the placebo-treated
monkeys in both models, the differ-
ent responses to TPO are most
remarkable.
in both models. Second, stromal damage resulting in sig-
nificantly impaired hematopoiesis has only been observed
following much greater doses of radiation [54] than those
used here. Nevertheless, we do not exclude the possibility
that the higher radiation dose of 8 Gy resulted in signifi-
cantly more damage and that the inflammatory reactions
to radiation exposure might have released cytokines which
counteracted the TPO efficacy in the transplant model.
The composition of the reconstituting cell populations
might be a decisive determinant for a clinically relevant
TPO response. In the 5 Gy myelosuppression model, the
residual cells are less than two orders of magnitude depleted
in stem cells and progenitor cells and remain in their normal
stromal environment. It is also clear from the kinetics of the
TPO response that its effectiveness is determined in the
initial phase after TBI, 
a conclusion that has
been corroborated by the
diminished response to
delayed administration of
TPO [55] as well as by
the observation in mice
that a single initial i.v.
injection of TPO is suffi-
cient to prevent profound
thrombocytopenia [28]. In
contrast, in the 8 Gy
model, there is a more
than 3 log stem cell depletion, and the hematopoietic recon-
stitution pattern observed was dependent on infused, highly
purified and progenitor-cell-depleted stem cells which
needed to home into the hematopoietic sites. It is conceiv-
able that in this situation initial hematopoietic reconstitution
cannot be stimulated by TPO alone and needs to be either
boosted by other growth factors or stimulated prior to TPO
treatment so as to generate TPO-responsive progenitor cells.
Since the TPO response was also severely diminished in the
unfractionated bone marrow recipients compared with the 5
Gy myelosuppressed monkeys which had similar platelet
reconstitution kinetics in the placebo control monkey, the
inefficacy of TPO and G-CSF cannot be attributed to the
depletion of progenitor cells but might also be due to poor
engraftment of the responsive progenitor cells. Finally,
these data indicate a steep decline of the TPO and G-CSF
responses with increasing radiation dose, a phenomenon
that has been observed for growth factors such as GM-CSF
[56] and IL-3 [57] as well. So, the accelerated hematopoi-
etic reconstitution after high-dose TBI originating from
either an autologous stem cell or unfractionated bone mar-
row graft would seem to gain little from exogenous growth
factors, possibly due to the relative lack of target cells,
which may already maximally proliferate due to endoge-
nous stimuli or are otherwise not accessible for exogenous
stimulation.
SINGLE-DOSE TPO ADMINISTRATION FOLLOWING
MYELOSUPPRESSIVE TREATMENT: SUFFICIENT
FOR PREVENTION OF THROMBOCYTOPENIA,
ACCELERATED RETICULOCYTE REGENERATION,
POTENTIATION OF THE RESPONSES TO G-CSF 
AND GM-CSF AND AUGMENTED BONE MARROW
CD34+ CELL RECONSTITUTION
A third study was undertaken A) to explore the option of
limiting the total dose of TPO, based on the previous studies
in mice [28] which showed that a single administration
of TPO might be sufficient to prevent thrombocytopenia
following cytoreductive
treatment, and B) to com-
pare the concurrent admin-
istration of TPO and
GM-CSF with that of
TPO and G-CSF and to
identify optimal growth
factor therapy to counter-
act both neutropenia and
thrombocytopenia.
Rhesus monkeys were
subjected to 5 Gy TBI,
inducing three weeks of
profound pancytopenia, and received either 5 µg/kg of TPO
i.v. at day 1 (i.e., 24 h after TBI), GM-CSF 25 µg/kg s.c. for
14 days, TPO and GM-CSF, G-CSF 10 µg/kg/d s.c. for 14
days, TPO and G-CSF, or placebo. Single i.v. dose treatment
with TPO one day after TBI effectively counteracted the need
for thrombocyte transfusions (provided whenever thrombo-
cyte levels were <40 · 109/l) and accelerated platelet reconsti-
tution to reach normal levels two weeks earlier than placebo
controls. TPO/GM-CSF was more effective than single-dose
TPO alone in stimulating thrombocyte regeneration, with a
less profound nadir and a further accelerated recovery to nor-
mal thrombocyte counts, as well as a slight overshoot to supra-
normal levels of thrombocytes. Monkeys treated with
TPO/GM-CSF uniformly did not require thrombocyte transfu-
sions, whereas those treated with GM-CSF alone needed two
to three transfusions, not dissimilar to the placebo-treated
monkeys, which required on average three (range two to six)
transfusions. Also, reticulocyte production was stimulated by
TPO and further augmented in monkeys treated with
TPO/GM-CSF. TPO alone did not stimulate neutrophil
regeneration, whereas GM-CSF shortened the period of neu-
trophils <0.5 · 109/l approximately one week; TPO/GM-CSF
treatment elevated the neutrophil nadir but did not further
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observed for growth factors such 
as GM-CSF and IL-3 as well.
accelerate recovery to normal values. TPO also augmented the
neutrophil response to G-CSF, resulting in similar patterns of
reconstitution following TPO/G-CSF and TPO/GM-CSF
treatment. The TPO/GM-CSF treatment resulted in a signifi-
cantly increased reconstitution of CD34+ bone marrow cells
and progenitor cells such as GM-CFU and BFU-E.
A single i.v. dose of TPO, administered one day after
TBI inducing three weeks of profound pancytopenia in
placebo-treated controls, appeared thus sufficient to virtu-
ally prevent the need for thrombocyte transfusion and to
accelerate thrombocyte reconstitution to normal levels by
two weeks. In a clinical setting, where the transfusion cri-
terion is generally set at a lower level of thrombocytes than
is feasible in monkeys, the TPO treatment would likely
have completely abol-
ished the thrombocyte
transfusion requirement
at this level of myelosup-
pression. Furthermore,
the results demonstrated
that TPO/GM-CSF and
TPO/G-CSF treatment
display distinct response
patterns among the three
major peripheral blood
cell types. Coadministra-
tion of TPO/GM-CSF
augmented thrombocyte,
red cell, and neutrophil
production over either of the individual growth factors alone,
whereas in the TPO/G-CSF treatment group only neutrophil
reconstitution appeared to benefit from the combination of
growth factors. However, the greater target cell range of the
TPO/GM-CSF combination should be balanced against the
slightly higher incidence of reported adverse effects of GM-
CSF [15-17], whereas the slightly more rapid reconstitution
of neutrophils following TPO/G-CSF administration should
be weighed against the reported dampening effect of G-CSF
treatment on thrombocyte recovery [24, 26, 39].
The observation that a single i.v. dose of TPO shortly
after intensive cytoreductive treatment is sufficient to signif-
icantly alleviate the course of thrombocytopenia is of con-
siderable practical and clinical importance. The finding is
consistent with data in mice [28], with the kinetics of TPO-
stimulated thrombocyte reconstitution in nonhuman primates
[24, 39], and with the decline in response when TPO admin-
istration was delayed [55]. These studies all point to a criti-
cal time phase early after TBI during which TPO has to be
administered to achieve an optimal response. The most obvi-
ous explanation is a decline in bone marrow TPO-responsive
target cells as a function of time, possibly due to the absence
of sufficiently high concentrations of TPO. This may either
be due to a physiological death function or apoptosis similar
to that identified for erythropoietin-deprived red cell progen-
itor cells [58, 59] or to protection of TPO-responsive pro-
genitors from radiation-induced cell death. Elucidation of
such mechanisms will not only provide further insight into the
physiological function of TPO, but will also be of consider-
able importance to achieve the maximum clinical benefit of
its therapeutic use. Although these data reveal that a single i.v.
dose of 5 µg/kg of TPO is sufficient to prevent thrombocy-
topenia at the level of myelosuppression chosen, this finding
does not preclude that clinical cytoreductive therapy requires
a more intensive TPO treatment regimen.
The administration of TPO/GM-CSF proved to be supe-
rior to all other growth
factors or combinations of
growth factors studied for
stimulating thrombocyte
reconstitution. GM-CSF
alone did not influence the
thrombocyte nadir or sig-
nificantly reduce the need
for thrombocyte transfu-
sions. However, it was as
effective as the single
administration of TPO
alone in stimulating post-
nadir thrombocyte pro-
duction. The augmented
thrombocyte reconstitution of the TPO/GM-CSF-treated
monkeys may reflect synergism of the two growth factors,
since the initial recovery of both thrombocytes and reticulo-
cytes in the TPO/GM-CSF group exceeded the sum of those
in the monkeys treated with either of the growth factors
alone. A stimulatory action of GM-CSF on megakaryocytes
resulting in increased thrombocyte production has been
described before [20, 60], although the results of in vivo
treatment with GM-CSF on thrombocyte reconstitution have
always been heterogenous [20, 60-62], and, in retrospect,
may have been codependent on variations in endogenous
thrombopoietin levels.
Surprisingly, the 10 µg/kg/d dose (for two weeks) of G-
CSF also appeared to stimulate thrombocyte production to a
certain extent, in contrast to the 5 µg/kg/d dose (for three
weeks) which in a previous study was used in the same non-
human primate model [24]. The reported effects of G-CSF on
thrombocyte production are not unambiguous, most reports
mentioning no effects at all [13, 63-65], some a positive
effect [66], and others a negative effect [67-69]. The obser-
vations in nonhuman primates follow essentially the same
pattern. We observed earlier in the same myelosuppression
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The observation that a single 
i.v. dose of TPO shortly after
intensive cytoreductive treatment 
is sufficient to significantly alleviate
the course of thrombocytopenia 
is of considerable practical and
clinical importance.
model as used here a dampening effect of G-CSF on TPO-
stimulated supranormal thrombocyte production [24]. This
was also seen in mice [26]. Meanwhile, in a transplant model
in rhesus monkeys involving 8 Gy TBI followed by infusion
of highly purified stem cells, protracted thrombocytopenia
significantly related to G-CSF treatment was encountered in
a few cases [27]. The causes of the variable reaction of
thrombocytes to G-CSF treatment are not elucidated and may
be governed by complex mechanisms; it should be noted that
G-CSF receptors are present on thrombocytes [70] as well as
on megakaryocytes, overexpression of G-CSF tending to
decrease the ploidy of megakaryocytes. We concluded pro-
visionally that combining TPO and G-CSF treatment may
have a variable, as yet unpredictable, and occasionally,
adverse outcome.
MECHANISMS OF TPO ACTION IN MYELOSUPPRESSED
MICE
The importance of dose and dose scheduling for multilin-
eage reconstitution after myelosuppressive TBI was further
evaluated in mice [71]. After 6 Gy TBI, a dose of 0.3 µg
TPO/mouse (12 µg/kg) i.p., zero to four h after TBI, pre-
vented the severe thrombocytopenia observed in control mice
and in addition stimulated red and white blood cell regenera-
tion. Time course studies revealed a gradual decline in efficacy
after an optimum within the first hours after TBI, accompanied
by a replacement of the multilineage effects by lineage-domi-
nant thrombopoietic stimulation. Pharmacokinetic (PK) data
demonstrated that i.p. injection resulted in maximum plasma
levels two h after administration. On the basis of the data we
inferred that a substantial level of TPO was required at a criti-
cal time interval after TBI to induce multilineage stimulation
of residual bone marrow cells. A more precise estimate of the
effect of dose and dose timing was provided by i.v. adminis-
tration of TPO, which showed an optimum immediately after
TBI and a sharp decline in efficacy between a dose of 0.1
µg/mouse (4 µg/kg; plasma level 60 ng/ml), which was fully
effective, and a dose of 0.03 µg/mouse (1.2 µg/kg; plasma level
20 ng/ml), which was largely ineffective. This observation is
interpreted as evidence for a threshold level of TPO required
for optimal efficacy. It was previously demonstrated [28,
78] that i.v. injection of 125I-rmTPO into mice results in an
initial sharp decline in plasma levels, followed by steady-state
clearance approximately three hours after i.v. injection [78].
A lower dose does not influence the terminal half life [28].
After i.v. bolus injection, the initial rapid decline in plasma
TPO levels is due to binding of TPO to c-mpl on platelets and
on cells in the spleen [78], whereas the slower terminal
decline is likely related to uptake and clearance by c-mpl on
platelets, spleen cells, and megakaryocytes, as well as non-
specific mechanisms [78, 79]. The initial binding and uptake
of TPO to c-mpl is concentration-dependent and becomes sat-
urated at higher doses leading to greater plasma TPO levels
[80]. This relationship between TPO pharmacokinetics and c-
mpl levels has recently been studied in normal mice, which
demonstrated that an i.v. dose of approximately 6 µg/kg (~0.15
µg/mouse) was needed to obtain an occupancy of 50% of c-
mpl sites. Doses greater than 6 µg/kg began to saturate this
specific clearance mechanism, whereas lower doses failed to
reach 50% receptor occupancy [80]. This is consistent with a
threshold level of TPO needed to overcome initial c-mpl-
mediated clearance and to result in sufficient plasma TPO lev-
els to achieve a maximal hemopoietic response. Doses larger
than 6 µg/kg (0.15 µg/mouse) may not provide any greater
efficacy. These data are consistent with demonstrating that the
hematopoietic recoveries after i.v. doses of 0.3 and 0.1
µg/mouse (12 and 4 µg/kg respectively) were not different,
whereas a dose of 0.03 µg/mouse (1.2 µg/kg) was subopti-
mal in preventing myelosuppression. Based on the previous
i.v. PK data comparing TPO plasma levels in c-mpl knock-
out and normal mice [78], it was inferred that 40% of the
exogenous TPO binds to c-mpl on platelets, and 60% is
available as free TPO in the plasma. Assuming a plasma
volume of 1 ml in a 25-g mouse, the suboptimal dose of 0.03
µg/mouse results in a maximum level of 20 ng/ml and the
effective dose of 0.1 µg/mouse in 60 ng/ml. Consequently, the
minimum effective or threshold plasma level is in between
those levels.
Fractionation of the dose of radiation and appropriate
dosing of TPO was thought to amplify the TPO effect on
immature cells to enable short-term transplantation assays.
Such an approach would also be more representative of clin-
ically used radiation regimens and of the protracted nature of
cytoreductive treatment by means of chemotherapy. Also
after fractionated TBI (3 · 3 Gy, 24 h apart), the optimal dose
and dose-scheduling of TPO derived from the 6 Gy experi-
ments, i.e., 0.3 µg/mouse, two h after each TBI fraction, pre-
vented thrombocytopenia and promoted erythrocyte and
leukocyte reconstitution. Using short-term transplantation
assays, i.e., colony-forming unit-spleen (CFU-S) day 13 and
the more immature cells with marrow repopulating ability
(MRA), it could be shown that TPO promoted CFU-S-13 and
transiently depleted MRA. The initial depletion of MRA in
response to TPO appeared to be replenished during long-
term reconstitution followed for a period of three months.
Apart from demonstrating again that MRA cells and CFU-S-
13 are separate functional entities, these data thus revealed
that TPO promotes short-term multilineage repopulating cells
at the expense of more immature ancestral cells, thereby pre-
venting pancytopenia. The short time interval available after
TBI to exert these effects demonstrates that TPO is able to
intervene in mechanisms which result in functional depletion
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of its multilineage target cells shortly after TBI and empha-
sizes the requirement of dose scheduling of TPO in keeping
with these mechanisms to obtain optimal clinical efficacy.
The mechanism by which TPO makes multilineage
cells available for accelerated hemopoietic reconstitution
remains to be further elucidated, as is their apparent func-
tional depletion as a function of time following TBI in the
absence of TPO. Multilineage TPO responsiveness
declined sharply as a function of time after TBI, leaving a
lineage-dominant thrombopoietic response when adminis-
tered 24 h after TBI. This indicates that in the absence of
TPO, multilineage TPO-responsive cells are rapidly
depleted or become inaccessible. The loss of the multilin-
eage TPO response may have diverse and complex causes,
which include apoptosis or radiation-induced cell death,
differentiation along other hemopoietic lineages, inhibition
mediated by cytokines produced in response to radiation
injury, or inaccessibility of the immature cells for TPO due
to stromal reactions to radiation. TPO has been shown to
prevent apoptosis of immature hemopoietic cells [72], and
this might be a prime candidate mechanism to explain the
short time interval available for optimally effective TPO
intervention. In vitro, TPO does not seem to confer a pro-
liferative response to immature hemopoietic cells but does
so strongly in the presence of suitable other factors, e.g.,
kit-ligand [8, 47, 73-77]. The mechanisms involved might
therefore include activation of one or more cofactors
required for the strong proliferative response observed. We
also do not exclude the possibility that the effect of TPO on
multilineage cells is augmented by the release of various
cytokines by megakaryocytes [41, 42] subsequent to stimu-
lation by TPO, although the time frame observed makes
such a mechanism unlikely.
Since the range of stimulation by TPO was not lineage-
specific, it was hypothesized that the effect was mediated by
stimulation of multilineage cells. Following transplantation of
bone marrow into lethally irradiated recipients, the number of
CFU-S-13 is a measure for relatively immature repopulating
stem cells [81], associated with the initial, short-term wave of
hemopoietic reconstitution, which lasts for several months
[82]. By this assay it was shown that the multilineage effect
of TPO administered two h after TBI is mediated through
stimulation of these immature cells and is already manifest 24
h after the last fraction of TBI. The number of secondary in
vitro clonogenic progenitors in the bone marrow of such
recipients is a measure of the MRA of the graft, the primary
cells being closely associated with those that provide sus-
tained hemopoiesis following bone marrow transplantation
[83]. MRA, measured by enumeration of GM-CFU numbers
in the bone marrow of mice injected with cells from TPO-
treated mice, appeared to be one to two orders of magnitude
less than in control mice. The increase of CFU-S-13 and the
concomitant decrease of cells with MRA most probably indi-
cate recruitment of multilineage short-term repopulating cells
from a more immature ancestral population. This is more con-
ceivable from the magnitude of this effect (14-fold for CFU-
S), which suggests three to four cell doublings. Since these
occurred during the three days which elapsed from the first
TPO administration to the time of the measurement, 24 h after
the last fraction of TBI, this would be in close agreement with
the doubling time established previously for such immature
cell populations during hemopoietic reconstitution [59]. The
decline in marrow repopulating cells with the concomitant
increase of spleen repopulating cells could also be considered
as a shift in homing pattern among these immature cells. To
date, there is no evidence to suggest that such a shift may
occur without cell divisions, whereas the ancestral position of
the marrow repopulating cells relative to the spleen colony-
forming cells has been well documented [83-85]. To date, the
effect of TPO treatment on long-term repopulating cells has
not been quantitatively documented. Recently, it was reported
that transplantation of bone marrow from TPO-treated, 3.5
Gy-irradiated donor mice facilitated the 90-day survival of the
recipient mice [86]. However, this survival effect had already
become established at the short-term hematopoietic reconsti-
tution parameter of 30-day survival (already in practice within
17 days), closely associated [82] to the CFU-S-13. Using such
an experimental design to establish TPO effects on long-term
repopulating cells would require a genetic marker able to dis-
tinguish between donor and recipient cells along multiple
hemopoietic lineages. TPO treatment shortly after much
higher (“supralethal”) doses of TBI promoted survival and
prevented bleeding [87]. 
The depletion of MRA cells in the TPO-treated mice,
measured 24 h after TBI, appeared to be transient. Peripheral
blood cell regeneration one and three months after three frac-
tions of 3 Gy was not different in mice treated with TPO com-
pared to controls and neither were the femoral and spleen in
vitro colony-forming cell numbers. Assessment of the MRA
at the same time intervals also did not reveal differences
between the TPO-treated mice and the placebo group. We
interpret these observations as replenishment of the MRA
cells from a more ancestral cell population with, by definition,
long-term repopulating ability, consistent with a model in
which MRA cells are a transitory population intermediate to
stem cells with long-term repopulating ability and the spleen
repopulating cells measured by the CFU-S-13 assay.
In vivo studies on TPO efficacy have yielded various
results; in normal animals, usually only a platelet response was
obtained [88-94], whereas in myelosuppressed animals multi-
lineage responses appeared to be the prevailing pattern [24, 25,
28, 39, 40, 86, 95-97]; following transplantation of limited
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numbers of stem cells, no response was obtained at all [27]. On
the basis of this heterogeneity, it can be assumed that the
response to exogenous TPO is determined by multiple factors.
We already pointed out the importance of cotreatment with G-
CSF or GM-CSF to make the TPO effect on GM-CFU recon-
stitution manifest in neutrophil numbers in the peripheral
blood. This study in mice also identified time relative to
myelosuppression and dose of exogenous TPO as pivotal fac-
tors. In addition, the difference between normal and myelo-
suppressed animals indicated that the TPO response of
immature cells might be dependent on the presence or activa-
tion of one or more cofactors. As already pointed out, TPO by
itself does not induce in vitro a proliferative response in imma-
ture bone marrow cells, but does so strongly in synergy with,
e.g., kit-ligand [8, 47, 73-77]. Identification of the cofactor(s)
which operate in irradiated or otherwise myelosuppressed ani-
mals to generate a proliferative response to TPO administra-
tion might therefore be highly relevant as well to improve the
clinical TPO response.
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